U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H24N2O8.H2O
Molecular Weight 462.4507
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DOXYCYCLINE

SMILES

C[C@@]1([H])c2cccc(c2C(=O)C3=C([C@]4([C@]([H])([C@@]([H])(C(=C(C4=O)C(=N)O)O)N(C)C)[C@]([H])([C@]13[H])O)O)O)O.O

InChI

InChIKey=XQTWDDCIUJNLTR-CVHRZJFOSA-N
InChI=1S/C22H24N2O8.H2O/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29;/h4-7,10,14-15,17,25,27-29,32H,1-3H3,(H2,23,31);1H2/t7-,10+,14+,15-,17-,22-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C22H24N2O8
Molecular Weight 444.4354
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Doxycycline is an antibacterial drug synthetically derived from oxytetracycline and used to treat a wide variety of bacterial infections, including those that cause acne. Doxycycline is used for bacterial pneumonia, acne, chlamydia infections, early Lyme disease, cholera, and syphilis. It is also useful for the treatment of malaria when used with quinine and for the prevention of malaria. Common side effects include diarrhea, nausea, vomiting, a red rash, and an increased risk of a sunburn. If used during pregnancy or in young children may result in permanent problems with the teeth including changes in their color. Its use during breastfeeding is probably safe. Like other tetracycline antibiotics, Doxycycline is protein synthesis inhibitors, inhibiting the binding of aminoacyl-tRNA to the mRNA-ribosome complex by binding to the 30S ribosomal subunit in the mRNA translation complex.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
VIBRAMYCIN

Approved Use

To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydia psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis (formerly Pasteurella pestis). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis). Cholera caused by Vibrio cholerae (formerly Vibrio comma). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes (formerly Aerobacter aerogenes). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae). Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Syphilis caused by Treponema pallidum. Yaws caused by Treponema pertenue. Listeriosis due to Listeria monocytogenes. Vincent's infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. Prophylaxis Doxycycline is indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (< 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains. See DOSAGE AND ADMINISTRATION section and Information for Patients subsection of the PRECAUTIONS section.

Launch Date

-6.5404801E10
Curative
VIBRAMYCIN

Approved Use

To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydia psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis (formerly Pasteurella pestis). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis). Cholera caused by Vibrio cholerae (formerly Vibrio comma). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes (formerly Aerobacter aerogenes). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae). Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Syphilis caused by Treponema pallidum. Yaws caused by Treponema pertenue. Listeriosis due to Listeria monocytogenes. Vincent's infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. Prophylaxis Doxycycline is indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (< 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains. See DOSAGE AND ADMINISTRATION section and Information for Patients subsection of the PRECAUTIONS section.

Launch Date

-6.5404801E10
Primary
VIBRAMYCIN

Approved Use

To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydia psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis (formerly Pasteurella pestis). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis). Cholera caused by Vibrio cholerae (formerly Vibrio comma). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes (formerly Aerobacter aerogenes). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae). Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Syphilis caused by Treponema pallidum. Yaws caused by Treponema pertenue. Listeriosis due to Listeria monocytogenes. Vincent's infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. Prophylaxis Doxycycline is indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (< 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains. See DOSAGE AND ADMINISTRATION section and Information for Patients subsection of the PRECAUTIONS section.

Launch Date

-6.5404801E10
Curative
VIBRAMYCIN

Approved Use

To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydia psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis (formerly Pasteurella pestis). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis). Cholera caused by Vibrio cholerae (formerly Vibrio comma). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes (formerly Aerobacter aerogenes). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae). Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Syphilis caused by Treponema pallidum. Yaws caused by Treponema pertenue. Listeriosis due to Listeria monocytogenes. Vincent's infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. Prophylaxis Doxycycline is indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (< 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains. See DOSAGE AND ADMINISTRATION section and Information for Patients subsection of the PRECAUTIONS section.

Launch Date

-6.5404801E10
Curative
VIBRAMYCIN

Approved Use

To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydia psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis (formerly Pasteurella pestis). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis). Cholera caused by Vibrio cholerae (formerly Vibrio comma). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes (formerly Aerobacter aerogenes). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae). Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Syphilis caused by Treponema pallidum. Yaws caused by Treponema pertenue. Listeriosis due to Listeria monocytogenes. Vincent's infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. Prophylaxis Doxycycline is indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (< 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains. See DOSAGE AND ADMINISTRATION section and Information for Patients subsection of the PRECAUTIONS section.

Launch Date

-6.5404801E10
Curative
Periostat

Approved Use

Uses temporarily relieves the minor aches and pains of muscles and joints associated with simple backache arthritis strains bruises sprains

Launch Date

-6.5491198E10
Curative
VIBRAMYCIN

Approved Use

To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydia psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis (formerly Pasteurella pestis). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis). Cholera caused by Vibrio cholerae (formerly Vibrio comma). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes (formerly Aerobacter aerogenes). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae). Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Syphilis caused by Treponema pallidum. Yaws caused by Treponema pertenue. Listeriosis due to Listeria monocytogenes. Vincent's infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. Prophylaxis Doxycycline is indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (< 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains. See DOSAGE AND ADMINISTRATION section and Information for Patients subsection of the PRECAUTIONS section.

Launch Date

-6.5491198E10
Curative
VIBRAMYCIN

Approved Use

To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydia psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis (formerly Pasteurella pestis). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis). Cholera caused by Vibrio cholerae (formerly Vibrio comma). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes (formerly Aerobacter aerogenes). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae). Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Syphilis caused by Treponema pallidum. Yaws caused by Treponema pertenue. Listeriosis due to Listeria monocytogenes. Vincent's infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. Prophylaxis Doxycycline is indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (< 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains. See DOSAGE AND ADMINISTRATION section and Information for Patients subsection of the PRECAUTIONS section.

Launch Date

-6.5491198E10
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.17 μg/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DOXYCYCLINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
32 μg × h/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DOXYCYCLINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10.5 h
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DOXYCYCLINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.86
unhealthy, 23.9
n = 190
Health Status: unhealthy
Condition: Urogenital Chlamydia trachomatis infection
Age Group: 23.9
Sex: M+F
Population Size: 190
Sources: Page: p.86
Disc. AE: Vomiting, Dysphagia...
AEs leading to
discontinuation/dose reduction:
Vomiting (0.5%)
Dysphagia (0.5%)
Hypersensitivity (0.5%)
Sources: Page: p.86
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.86
unhealthy, 24.1
n = 188
Health Status: unhealthy
Condition: Urogenital Chlamydia trachomatis infection
Age Group: 24.1
Sex: M+F
Population Size: 188
Sources: Page: p.86
Disc. AE: Headache, Hypersensitivity...
AEs leading to
discontinuation/dose reduction:
Headache (0.5%)
Hypersensitivity (0.5%)
Sources: Page: p.86
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.114
unhealthy, 24.7
n = 223
Health Status: unhealthy
Condition: Chlamydia trachomatis endocervical infection
Age Group: 24.7
Sex: F
Population Size: 223
Sources: Page: p.114
Disc. AE: Dyspepsia, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Dyspepsia (0.45%)
Abdominal pain (0.45%)
Nausea (0.45%)
Vomiting (0.45%)
Chest pain (0.45%)
Dyspnea (0.45%)
Sources: Page: p.114
40 mg 1 times / day steady, oral
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adults
n = 84
Health Status: unhealthy
Condition: Papulopustular Rosacea
Age Group: adults
Population Size: 84
Sources:
Other AEs: Chest pain, Abortion spontaneous...
Other AEs:
Chest pain (serious, 1 patient)
Abortion spontaneous (serious, 1 patient)
Nausea (below serious, 3 patients)
Sinusitis (below serious, 3 patients)
Sources:
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 15
Health Status: unhealthy
Condition: Proliferative Diabetic Retinopathy
Population Size: 15
Sources:
Other AEs: Pulmonary embolism, Umbilical hernia...
Other AEs:
Pulmonary embolism (serious, 1 patient)
Umbilical hernia (serious, 1 patient)
Vomiting (serious, 1 patient)
Constipation (below serious, 1 patient)
Fatigue (below serious, 1 patient)
Gout (below serious, 1 patient)
Headaches (below serious, 2 patients)
Prostatitis (below serious, 1 patient)
Urinary retention (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dysphagia 0.5%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.86
unhealthy, 23.9
n = 190
Health Status: unhealthy
Condition: Urogenital Chlamydia trachomatis infection
Age Group: 23.9
Sex: M+F
Population Size: 190
Sources: Page: p.86
Hypersensitivity 0.5%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.86
unhealthy, 23.9
n = 190
Health Status: unhealthy
Condition: Urogenital Chlamydia trachomatis infection
Age Group: 23.9
Sex: M+F
Population Size: 190
Sources: Page: p.86
Vomiting 0.5%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.86
unhealthy, 23.9
n = 190
Health Status: unhealthy
Condition: Urogenital Chlamydia trachomatis infection
Age Group: 23.9
Sex: M+F
Population Size: 190
Sources: Page: p.86
Headache 0.5%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.86
unhealthy, 24.1
n = 188
Health Status: unhealthy
Condition: Urogenital Chlamydia trachomatis infection
Age Group: 24.1
Sex: M+F
Population Size: 188
Sources: Page: p.86
Hypersensitivity 0.5%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.86
unhealthy, 24.1
n = 188
Health Status: unhealthy
Condition: Urogenital Chlamydia trachomatis infection
Age Group: 24.1
Sex: M+F
Population Size: 188
Sources: Page: p.86
Abdominal pain 0.45%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.114
unhealthy, 24.7
n = 223
Health Status: unhealthy
Condition: Chlamydia trachomatis endocervical infection
Age Group: 24.7
Sex: F
Population Size: 223
Sources: Page: p.114
Chest pain 0.45%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.114
unhealthy, 24.7
n = 223
Health Status: unhealthy
Condition: Chlamydia trachomatis endocervical infection
Age Group: 24.7
Sex: F
Population Size: 223
Sources: Page: p.114
Dyspepsia 0.45%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.114
unhealthy, 24.7
n = 223
Health Status: unhealthy
Condition: Chlamydia trachomatis endocervical infection
Age Group: 24.7
Sex: F
Population Size: 223
Sources: Page: p.114
Dyspnea 0.45%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.114
unhealthy, 24.7
n = 223
Health Status: unhealthy
Condition: Chlamydia trachomatis endocervical infection
Age Group: 24.7
Sex: F
Population Size: 223
Sources: Page: p.114
Nausea 0.45%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.114
unhealthy, 24.7
n = 223
Health Status: unhealthy
Condition: Chlamydia trachomatis endocervical infection
Age Group: 24.7
Sex: F
Population Size: 223
Sources: Page: p.114
Vomiting 0.45%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.114
unhealthy, 24.7
n = 223
Health Status: unhealthy
Condition: Chlamydia trachomatis endocervical infection
Age Group: 24.7
Sex: F
Population Size: 223
Sources: Page: p.114
Nausea below serious, 3 patients
40 mg 1 times / day steady, oral
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adults
n = 84
Health Status: unhealthy
Condition: Papulopustular Rosacea
Age Group: adults
Population Size: 84
Sources:
Sinusitis below serious, 3 patients
40 mg 1 times / day steady, oral
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adults
n = 84
Health Status: unhealthy
Condition: Papulopustular Rosacea
Age Group: adults
Population Size: 84
Sources:
Abortion spontaneous serious, 1 patient
40 mg 1 times / day steady, oral
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adults
n = 84
Health Status: unhealthy
Condition: Papulopustular Rosacea
Age Group: adults
Population Size: 84
Sources:
Chest pain serious, 1 patient
40 mg 1 times / day steady, oral
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adults
n = 84
Health Status: unhealthy
Condition: Papulopustular Rosacea
Age Group: adults
Population Size: 84
Sources:
Constipation below serious, 1 patient
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 15
Health Status: unhealthy
Condition: Proliferative Diabetic Retinopathy
Population Size: 15
Sources:
Fatigue below serious, 1 patient
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 15
Health Status: unhealthy
Condition: Proliferative Diabetic Retinopathy
Population Size: 15
Sources:
Gout below serious, 1 patient
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 15
Health Status: unhealthy
Condition: Proliferative Diabetic Retinopathy
Population Size: 15
Sources:
Prostatitis below serious, 1 patient
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 15
Health Status: unhealthy
Condition: Proliferative Diabetic Retinopathy
Population Size: 15
Sources:
Urinary retention below serious, 1 patient
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 15
Health Status: unhealthy
Condition: Proliferative Diabetic Retinopathy
Population Size: 15
Sources:
Headaches below serious, 2 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 15
Health Status: unhealthy
Condition: Proliferative Diabetic Retinopathy
Population Size: 15
Sources:
Pulmonary embolism serious, 1 patient
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 15
Health Status: unhealthy
Condition: Proliferative Diabetic Retinopathy
Population Size: 15
Sources:
Umbilical hernia serious, 1 patient
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 15
Health Status: unhealthy
Condition: Proliferative Diabetic Retinopathy
Population Size: 15
Sources:
Vomiting serious, 1 patient
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 15
Health Status: unhealthy
Condition: Proliferative Diabetic Retinopathy
Population Size: 15
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer








Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
PubMed

PubMed

TitleDatePubMed
Evaluation of a new antibacterial agent. Doxycycline monohydrate and doxycycline hyclate (Vibramycin).
1969 Jul 28
Phototoxic potential of minocycline and doxycycline.
1972 May
The absorption and sputum penetration of doxycycline.
1978 Nov
Pharmacokinetics and tolerability of a single oral 600-mg dose of doxycycline.
1979 Jun 16
[Leukocytoclastic vasculitis due to drug allergy presenting as generalized pustular exanthema].
1981 Sep
Screening for new compounds with antiherpes activity.
1984 Oct
Tetracycline-induced renal hypophosphatemia in a patient with a syndrome of inappropriate secretion of antidiuretic hormone.
1988
Inhibition of HIV-1 RNA-dependent DNA polymerase and cellular DNA polymerases alpha, beta and gamma by phosphonoformic acid and other drugs.
1988 Feb
Anosmia after doxycycline use.
1990 Apr 16
Protective activity of tetracycline analogs against the cytopathic effect of the human immunodeficiency viruses in CEM cells.
1990 Jan-Feb
In vitro and in vivo effects of doxycycline on Toxoplasma gondii.
1990 May
Asymptomatic neurosyphilis after doxycycline therapy for early latent syphilis.
1993 Nov-Dec
Quinine toxicity when given with doxycycline and mefloquine.
1994 Jun
In vitro model to assess effect of antimicrobial agents on Encephalitozoon cuniculi.
1994 Oct
Carbamazepine-induced hyponatremia resolved with doxycycline.
1995 Aug
Human neutrophil collagenase (MMP-8), identified in bronchiectasis BAL fluid, correlates with severity of disease.
1995 Jun
[The influence of selected antibiotics on the central action of aminophyllines--experimental studies].
1996
Influence of antimicrobial agents on replication and stage conversion of Toxoplasma gondii.
1996
Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro.
1996 Dec
Short report: severe hiccups secondary to doxycycline-induced esophagitis during treatment of malaria.
1996 Feb
Histologic effect of doxycycline sclerotherapy on rat femoral nerve.
1996 Nov-Dec
Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline. Nordic Atypical Pneumonia Study Group.
1997 Apr
Ataxia following docetaxel infusion.
1997 Aug
Doxycycline-induced lithium toxicity.
1997 Feb
Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium.
1997 May
Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination.
1998 Dec
Neurotic effects of doxycycline sclerotherapy.
1998 Mar
De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor model.
2009 Dec 1
Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection.
2009 May
Doxycycline-induced dizziness in dental patient. Case report.
2010 Aug-Sep
Original quinazoline derivatives displaying antiplasmodial properties.
2010 Feb
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression.
2010 Feb 2
Chloramphenicol causes mitochondrial stress, decreases ATP biosynthesis, induces matrix metalloproteinase-13 expression, and solid-tumor cell invasion.
2010 Jul
Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea.
2010 Jun
Integrin-linked kinase is involved in cocaine sensitization by regulating PSD-95 and synapsin I expression and GluR1 Ser845 phosphorylation.
2010 Mar
Angiotensin-(1-7) ameliorates myocardial remodeling and interstitial fibrosis in spontaneous hypertension: role of MMPs/TIMPs.
2010 Nov 30
Azelaic acid gel 15% in the management of papulopustular rosacea: a status report on available efficacy data and clinical application.
2011 Aug
Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.
2011 Dec 22
Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: a study of 14 patients.
2011 May-Jun
Molecular effects of doxycycline treatment on pterygium as revealed by massive transcriptome sequencing.
2012
Aryl hydrocarbon receptor protects lung adenocarcinoma cells against cigarette sidestream smoke particulates-induced oxidative stress.
2012 Mar 15
Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs.
2012 May
Tandem synthesis and in vitro antiplasmodial evaluation of new naphtho[2,1-d]thiazole derivatives.
2012 Sep
Differential action of monohydroxylated polycyclic aromatic hydrocarbons with estrogen receptors α and β.
2013 Apr
A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs.
2013 Dec 17
FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1.
2013 Sep 5
A simple transcriptomic signature able to predict drug-induced hepatic steatosis.
2014 Apr
In vitro antiplasmodial activity of some medicinal plants of Burkina Faso.
2014 Jan
A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity.
2014 Jan
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Sample Use Guides

Periostat (Doxycycline hyclate) 20 mg twice daily as an adjunct following scaling and root planing may be administered for up to 9 TM months. Safety beyond 12 months and efficacy beyond 9 months have not been established. Periostat should be administered at least one hour prior to morning and evening meals
Route of Administration: Oral
PC3 cells were incubated with LPS (0.5 μg/mL) for 24 h in the presence or absence of doxycycline (5 μg/mL). The effects of LPS and doxycycline on the expressions of MMP-2, MMP-8, MMP-9, MMP-10, NF-κB/p65, IκB-α, p-IκB-α, IKK-β were examined by Western blotting and immunohistochemistry in PC3 cells. LPS increased expression and activity of MMP-9 and expression of MMP-8, MMP-10, NF-κB /p65, p-IκB-α, IKK-β and doxycycline down-regulated its effects with the exception of MMP-10 expression.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:59:29 UTC 2021
Edited
by admin
on Fri Jun 25 20:59:29 UTC 2021
Record UNII
N12000U13O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DOXYCYCLINE
MART.   MI   ORANGE BOOK   USAN   USP   VANDF  
USAN  
Official Name English
DOXYCYCLINE [MI]
Common Name English
DOXYCYCLINE MONOHYDRATE [EP]
Common Name English
SUPRACYCLIN
Brand Name English
DOXYCYCLINE [USAN]
Common Name English
DOXYCYCLINE [ORANGE BOOK]
Common Name English
ORACEA
Brand Name English
DOXYCYCLINE MONOHYDRATE [VANDF]
Common Name English
DOXYCYCLINE MONOHYDRATE [USP-RS]
Common Name English
2-NAPHTHACENECARBOXAMIDE, 4-(DIMETHYLAMINO)-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,5,10,12,12A-PENTAHYDROXY-6-METHYL-1,11-DIOXO-, (4S-(4.ALPHA.,4A.ALPHA.,5.ALPHA.,5A.ALPHA.6.ALPHA.,12A.ALPHA.))-, MONOHYDRATE
Common Name English
DOXYCYCLINE MONOHYDRATE [WHO-DD]
Common Name English
DOXYCYCLINE [VANDF]
Common Name English
DOXYCYCLINE MONOHYDRATE [MART.]
Common Name English
DOXIROBE
Brand Name English
DOXYCYCLINE MONOHYDRATE [EP MONOGRAPH]
Common Name English
DOXYCYCLINE [USP MONOGRAPH]
Common Name English
DOXYLIN
Brand Name English
DOXYCYCLINE (EMA EPAR: VETERINARY)
Common Name English
MONODOX
Brand Name English
GS-3065
Code English
XYROSA
Brand Name English
DOXYCYCLINE MONOHYDRATE
EP   MART.   VANDF   WHO-DD  
Common Name English
DOXYCHEL
Brand Name English
4-(DIMETHYLAMINO)-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,5,10,12,12A-PENTAHYDROXY-6-METHYL-1,11-DIOXO-2-NAPHTHACENECARBOXAMIDE MONOHYDRATE
Common Name English
Classification Tree Code System Code
WHO-VATC QA01AB22
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
WHO-ATC J01AA02
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.2
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
NDF-RT N0000007948
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.5.3.2
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
WHO-ATC A01AB22
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
NCI_THESAURUS C1595
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
NDF-RT N0000007948
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
EMA VETERINARY ASSESSMENT REPORTS DOXIROBE
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
WHO-VATC QJ01AA02
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.5.3.1
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
LIVERTOX 329
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
NDF-RT N0000175882
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
Code System Code Type Description
IUPHAR
6464
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
PRIMARY
DRUG BANK
DB00254
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
PRIMARY
MESH
D004318
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
PRIMARY
ChEMBL
CHEMBL1433
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
PRIMARY
MERCK INDEX
M4758
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
PRIMARY Merck Index
RXCUI
203122
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
PRIMARY
RXCUI
3640
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
ALTERNATIVE
CAS
17086-28-1
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
PRIMARY
FDA UNII
N12000U13O
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
PRIMARY
EVMPD
SUB01832MIG
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
PRIMARY
NCI_THESAURUS
C457
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
PRIMARY
LACTMED
Doxycycline
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
PRIMARY
WIKIPEDIA
DOXYCYCLINE
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
PRIMARY
USP_CATALOG
1225984
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
PRIMARY USP-RS
DRUG CENTRAL
961
Created by admin on Fri Jun 25 20:59:29 UTC 2021 , Edited by admin on Fri Jun 25 20:59:29 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
BINDER->LIGAND
BINDING
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC POPULATION: END-STAGE RENAL DISEASE

MIC BIOLOGICAL PATHOGEN: NOCARDIAE AND OTHER AEROBIC ACTNOMYCES spp.

SUSCEPTIBILITY: RESISTANT

MIC BIOLOGICAL PATHOGEN: ACINETOBACTER spp., ENTEROBACTERIACEAE, FRANCISELLA TULARENSIS, VIBRIO CHOLREA, YERSINIA PESTIS

SUSCEPTIBILITY: RESISTANT

MIC BIOLOGICAL SUSCEPTIBILITY: SUSCEPTIBLE

PATHOGEN: ACINETOBACTER spp., ENTEROBACTERIACEAE, FRANCISELLA TULARENSIS, VIBRIO CHOLREA, YERSINIA PESTIS

MIC BIOLOGICAL SUSCEPTIBILITY: INTERMEDIATE

PATHOGEN: ACINETOBACTER spp., ENTEROBACTERIACEAE, FRANCISELLA TULARENSIS, VIBRIO CHOLREA, YERSINIA PESTIS

MIC BIOLOGICAL SUSCEPTIBILITY: INTERMEDIATE

PATHOGEN: NOCARDIAE AND OTHER AEROBIC ACTNOMYCES spp.

MIC BIOLOGICAL PATHOGEN: S. PNEUMONIAE

SUSCEPTIBILITY: INTERMEDIATE

Tmax PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

FORMULATION: IMMEDIATE RELEASE

MIC BIOLOGICAL SUSCEPTIBILITY: RESISTANT

PATHOGEN: S. PNEUMONIAE

Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

FORMULATION: DELAYED-RELEASE TABLET

MIC BIOLOGICAL SUSCEPTIBILITY: SUSCEPTIBLE

PATHOGEN: NOCARDIAE AND OTHER AEROBIC ACTNOMYCES spp., BRUCELLA spp., BACILLUS ANTRHACIS

MIC BIOLOGICAL SUSCEPTIBILITY: SUSCEPTIBLE

PATHOGEN: S. PNEUMONIAE